Related Experiment Video

Updated: Oct 30, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer

Yun Jung Choi1, Hyeonjeong Lee2, Da-Som Kim2

  • 1Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul 05505, South Korea.

European Journal of Pharmacology
|July 5, 2021
PubMed

Insights

A new drug, YPN-005, shows promise for treating small cell lung cancer (SCLC). This cyclin-dependent kinase 7 (CDK7) inhibitor effectively reduced SCLC tumor growth and worked in drug-resistant cells and patient organoids.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Small cell lung cancer (SCLC) lacks effective therapies, unlike non-small cell lung cancer.
  • Despite advancements in targeted agents and immunotherapies, novel treatments for SCLC are urgently required.
  • Acquired resistance to conventional chemotherapy (cisplatin, etoposide) presents a significant clinical challenge in SCLC.

Purpose of the Study:

  • To evaluate the anticancer potential of YPN-005, a novel cyclin-dependent kinase 7 (CDK7) inhibitor, against SCLC.
  • To assess YPN-005's efficacy in SCLC cell lines, chemoresistant cells, and patient-derived organoids.
  • To investigate the mechanism of action of YPN-005, focusing on RNA polymerase II phosphorylation.

Main Methods:

  • Kinase selectivity assay for YPN-005 against CDK7.
  • Antiproliferative assays in SCLC and drug-resistant cell lines.
  • Assessment of RNA polymerase II C-terminal domain phosphorylation.
  • In vivo tumor growth inhibition studies.
  • Evaluation of YPN-005 in patient-derived SCLC organoids compared to THZ1.

Main Results:

  • YPN-005 demonstrated high selectivity for CDK7.
  • The inhibitor exhibited significant antiproliferative effects in SCLC and resistant cell lines.
  • YPN-005 effectively reduced RNA polymerase II phosphorylation, inhibiting tumor growth.
  • YPN-005 showed superior efficacy in patient-derived SCLC organoids compared to THZ1.

Conclusions:

  • Targeting CDK7 is a viable therapeutic strategy for SCLC.
  • YPN-005 is a potent CDK7 inhibitor with significant anticancer activity in preclinical SCLC models.
  • YPN-005 represents a promising therapeutic candidate for both primary and resistant SCLC.
Keywords:
CDK7 inhibitorResistanceSmall cell cancer (SCC)Targeted therapy

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.2K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K